肝硬化的发展趋势:病因、并发症和合并症

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Digestive and Liver Disease Pub Date : 2024-09-01 DOI:10.1016/j.dld.2024.08.021
E. Errigo, R. Mizzi, A. Lombardo, V. Calvaruso, G. Di Maria, F. Simone, N. Alessi, G. Cabibbo, S. Petta, C. Celsa, S. Peralta, M. Peralta, C. Cammà, V. Di Marco
{"title":"肝硬化的发展趋势:病因、并发症和合并症","authors":"E. Errigo,&nbsp;R. Mizzi,&nbsp;A. Lombardo,&nbsp;V. Calvaruso,&nbsp;G. Di Maria,&nbsp;F. Simone,&nbsp;N. Alessi,&nbsp;G. Cabibbo,&nbsp;S. Petta,&nbsp;C. Celsa,&nbsp;S. Peralta,&nbsp;M. Peralta,&nbsp;C. Cammà,&nbsp;V. Di Marco","doi":"10.1016/j.dld.2024.08.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The epidemiology of liver cirrhosis is evolving and the etiology, complications, and comorbidities of cirrhosis are continuously changing, presenting new challenges.</p></div><div><h3>Methods</h3><p>We reported data from an observational, monocentric study including 1,617 patients with liver cirrhosis admitted to our liver unit from January 2014 to December 2023.</p></div><div><h3>Results</h3><p>The mean age of patients was 66.8 years, with a male predominance except for autoimmune etiology. During the observation period, the number of hospitalized patients with active HCV infection decreased from 47.9% in 2014 to 9.2% in 2023, while patients with HCV cirrhosis in sustained virologic response (SVR) increased from 15.6% in 2014 to 26.2% in 2023. Hospitalizations for HBV-related cirrhosis remained stable (5.5% in 2014 and 8.5% in 2023. Patients for alcohol-related cirrhosis increased from 16.6% in 2014 to 23.9% 2023 and patients with metabolic cirrhosis increased from 10.6% in 2014 to 36.8% in 2023. The rate of patients with autoimmune cirrhosis (3.0% in 2014 and 4.2% in 2023) and cryptogenic cirrhosis (6.0% in 2014 to 7.9% in 2023) remained stable over the years. Patients with alcohol-related cirrhosis (mean age 59.5 years), HBV cirrhosis (62.1 years) and autoimmune etiologies (62.2 years) were younger than patients with HCV cirrhosis (69.3 years), metabolic cirrhosis (68.3 years) and cryptogenic cirrhosis (67.6 years). The most frequent complication for hospitalization was HCC in active (47.8%) and SVR (58.2%) HCV cirrhosis, and in HBV cirrhosis (47.3%), with the ascites was more frequent in alcohol-related (45.8%) and metabolic (34.1%) cirrhosis Patients with metabolic cirrhosis had the most extrahepatic comorbidities (66.3% diabetic, 18.0% chronic kidney disease, and 20.7% heart disease).</p></div><div><h3>Conclusions</h3><p>Liver cirrhosis epidemiology is changing, with decreasing HCV infections but increasing alcohol-related and metabolic cases. Complications and comorbidities require tailored management strategies. Effective public health interventions and adaptive healthcare approaches are crucial to address these evolving challenges.</p></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"56 ","pages":"Page S324"},"PeriodicalIF":4.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolving trends in liver cirrhosis: etiology, complications and comorbidities\",\"authors\":\"E. Errigo,&nbsp;R. Mizzi,&nbsp;A. Lombardo,&nbsp;V. Calvaruso,&nbsp;G. Di Maria,&nbsp;F. Simone,&nbsp;N. Alessi,&nbsp;G. Cabibbo,&nbsp;S. Petta,&nbsp;C. Celsa,&nbsp;S. Peralta,&nbsp;M. Peralta,&nbsp;C. Cammà,&nbsp;V. Di Marco\",\"doi\":\"10.1016/j.dld.2024.08.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The epidemiology of liver cirrhosis is evolving and the etiology, complications, and comorbidities of cirrhosis are continuously changing, presenting new challenges.</p></div><div><h3>Methods</h3><p>We reported data from an observational, monocentric study including 1,617 patients with liver cirrhosis admitted to our liver unit from January 2014 to December 2023.</p></div><div><h3>Results</h3><p>The mean age of patients was 66.8 years, with a male predominance except for autoimmune etiology. During the observation period, the number of hospitalized patients with active HCV infection decreased from 47.9% in 2014 to 9.2% in 2023, while patients with HCV cirrhosis in sustained virologic response (SVR) increased from 15.6% in 2014 to 26.2% in 2023. Hospitalizations for HBV-related cirrhosis remained stable (5.5% in 2014 and 8.5% in 2023. Patients for alcohol-related cirrhosis increased from 16.6% in 2014 to 23.9% 2023 and patients with metabolic cirrhosis increased from 10.6% in 2014 to 36.8% in 2023. The rate of patients with autoimmune cirrhosis (3.0% in 2014 and 4.2% in 2023) and cryptogenic cirrhosis (6.0% in 2014 to 7.9% in 2023) remained stable over the years. Patients with alcohol-related cirrhosis (mean age 59.5 years), HBV cirrhosis (62.1 years) and autoimmune etiologies (62.2 years) were younger than patients with HCV cirrhosis (69.3 years), metabolic cirrhosis (68.3 years) and cryptogenic cirrhosis (67.6 years). The most frequent complication for hospitalization was HCC in active (47.8%) and SVR (58.2%) HCV cirrhosis, and in HBV cirrhosis (47.3%), with the ascites was more frequent in alcohol-related (45.8%) and metabolic (34.1%) cirrhosis Patients with metabolic cirrhosis had the most extrahepatic comorbidities (66.3% diabetic, 18.0% chronic kidney disease, and 20.7% heart disease).</p></div><div><h3>Conclusions</h3><p>Liver cirrhosis epidemiology is changing, with decreasing HCV infections but increasing alcohol-related and metabolic cases. Complications and comorbidities require tailored management strategies. Effective public health interventions and adaptive healthcare approaches are crucial to address these evolving challenges.</p></div>\",\"PeriodicalId\":11268,\"journal\":{\"name\":\"Digestive and Liver Disease\",\"volume\":\"56 \",\"pages\":\"Page S324\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive and Liver Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S159086582400940X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S159086582400940X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景肝硬化的流行病学在不断发展,肝硬化的病因、并发症和合并症也在不断变化,给我们带来了新的挑战。方法我们报告了一项观察性、单中心研究的数据,包括2014年1月至2023年12月我院肝病科收治的1617例肝硬化患者。在观察期内,活动性HCV感染住院患者人数从2014年的47.9%降至2023年的9.2%,而持续病毒学应答(SVR)的HCV肝硬化患者从2014年的15.6%增至2023年的26.2%。HBV 相关肝硬化住院率保持稳定(2014 年为 5.5%,2023 年为 8.5%)。酒精相关肝硬化患者从2014年的16.6%增至2023年的23.9%,代谢性肝硬化患者从2014年的10.6%增至2023年的36.8%。自身免疫性肝硬化(2014 年为 3.0%,2023 年为 4.2%)和隐源性肝硬化(2014 年为 6.0%,2023 年为 7.9%)患者的比例多年来保持稳定。酒精相关性肝硬化(平均年龄59.5岁)、HBV肝硬化(62.1岁)和自身免疫性肝硬化(62.2岁)患者的年龄比HCV肝硬化(69.3岁)、代谢性肝硬化(68.3岁)和隐源性肝硬化(67.6岁)患者年轻。在活动性(47.8%)和 SVR(58.2%)HCV 肝硬化以及 HBV 肝硬化(47.3%)中,最常见的住院并发症是 HCC,腹水在酒精相关性(45.8%)和代谢性(34.1%)肝硬化中更为常见。结论肝硬化流行病学正在发生变化,HCV 感染减少,但酒精相关和代谢性病例增加。并发症和合并症需要有针对性的管理策略。有效的公共卫生干预措施和适应性医疗保健方法对于应对这些不断变化的挑战至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evolving trends in liver cirrhosis: etiology, complications and comorbidities

Background

The epidemiology of liver cirrhosis is evolving and the etiology, complications, and comorbidities of cirrhosis are continuously changing, presenting new challenges.

Methods

We reported data from an observational, monocentric study including 1,617 patients with liver cirrhosis admitted to our liver unit from January 2014 to December 2023.

Results

The mean age of patients was 66.8 years, with a male predominance except for autoimmune etiology. During the observation period, the number of hospitalized patients with active HCV infection decreased from 47.9% in 2014 to 9.2% in 2023, while patients with HCV cirrhosis in sustained virologic response (SVR) increased from 15.6% in 2014 to 26.2% in 2023. Hospitalizations for HBV-related cirrhosis remained stable (5.5% in 2014 and 8.5% in 2023. Patients for alcohol-related cirrhosis increased from 16.6% in 2014 to 23.9% 2023 and patients with metabolic cirrhosis increased from 10.6% in 2014 to 36.8% in 2023. The rate of patients with autoimmune cirrhosis (3.0% in 2014 and 4.2% in 2023) and cryptogenic cirrhosis (6.0% in 2014 to 7.9% in 2023) remained stable over the years. Patients with alcohol-related cirrhosis (mean age 59.5 years), HBV cirrhosis (62.1 years) and autoimmune etiologies (62.2 years) were younger than patients with HCV cirrhosis (69.3 years), metabolic cirrhosis (68.3 years) and cryptogenic cirrhosis (67.6 years). The most frequent complication for hospitalization was HCC in active (47.8%) and SVR (58.2%) HCV cirrhosis, and in HBV cirrhosis (47.3%), with the ascites was more frequent in alcohol-related (45.8%) and metabolic (34.1%) cirrhosis Patients with metabolic cirrhosis had the most extrahepatic comorbidities (66.3% diabetic, 18.0% chronic kidney disease, and 20.7% heart disease).

Conclusions

Liver cirrhosis epidemiology is changing, with decreasing HCV infections but increasing alcohol-related and metabolic cases. Complications and comorbidities require tailored management strategies. Effective public health interventions and adaptive healthcare approaches are crucial to address these evolving challenges.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Digestive and Liver Disease
Digestive and Liver Disease 医学-胃肠肝病学
CiteScore
6.10
自引率
2.20%
发文量
632
审稿时长
19 days
期刊介绍: Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.
期刊最新文献
Full Title Page /Editorial Board Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: A long-term prospective cohort study. Porto-sinusoidal vascular disorder with known etiologies had more severe portal hypertension and poorer outcomes. Small bowel metastasis from pulmonary pleomorphic carcinoma. Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1